| Dear Savvy Investor, Something VERY rare happened on Thursday, and I want to make sure you got a heads-up so you can act quickly. David Gardner, legendary investor and head of the Motley Fool Rule Breakers stock-picking service, recommended a new stock to Rule Breakers members. The reason I'm so excited? It's the newest recommendation in the rapidly growing field of biotech... and David's previous biotech picks have an incredible track record so far. And while I can't tell you the names of David's OTHER recommendations in this cutting-edge field... ... I can tell you why I think it pays to listen to David. Just take a look at what happened to some of David's previous biotech recommendations in Rule Breakers: - I▮▮▮▮▮▮, up 3,481% since 2005 rec
- B▮▮▮▮▮▮, up 384% since 2007 rec
- G▮▮▮▮▮▮, up 138% since 2018 rec
If you had invested $1,000 in each of those biotech companies when David recommended them, you'd be sitting on $43,030 right now. And on Thursday, David just revealed his latest biotech healthcare pick. Of course, I can't guarantee that you'll see 10X returns on this new pick, too. But I can tell you exactly why I think David's new pick could revolutionize the medical field... ... and why investors should pay attention. Right now, over 15,112,098 Americans are living with cancer. 38% of adults will be diagnosed with cancer in their lives. It is a sad reality as human lifespans increase: we all will, in some way, be touched by cancer. And David's latest recommendation is doing something about it. This small healthcare company is revolutionizing cancer treatment, tackling the "holy grail" of cancer treatment. And in doing so, they're pushing a $147 billion cancer industry into the future. A small percentage of the estimated 23,000 new brain cancer cases in the U.S. this year could experience a smoother, less invasive form of treatment, courtesy of this still-small company. And as undeniably exciting as that news is... that's practically old news for this agile young company. They've already begun debuting other new forms of cancer treatment, and the promise behind their innovations is astounding. As more and more private insurers approve their technology, hundreds of thousands of lives could be saved by this company's inventions... which means billions of dollars could also be saved for American's expensive healthcare system. David believes this company could be a game-changer for the healthcare industry. And with less than 1% of a $147 billion addressable market, this still-small company has a massive runway. But unless you're a Rule Breakers member, you simply won't be able to find out about David's remarkable new recommendation. If you have any interest in being among the first group of investors to capitalize on David's latest Rule Breakers recommendation, this is your chance. | 
没有评论:
发表评论